100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
1443421-69-9Abacavir EP Impurity B
● In Stock
| Catalogue No.: | VL760001 |
|---|---|
| CAS No.: | 1443421-69-9 |
| Mol. Formula: | C18H21ClN10O |
| Mol. Weight: | 428.8 g/mol |
Additional information on CAS 1443421-69-9
Parent drug
AbacavirIUPAC Name
6-(Cyclopropylamino)-9-[(1R, 4S)-4-[[(2, 5-diamino-6-chloropyrimidin-4-yl)oxy]methyl]cyclopent-2-enyl]-9H-purine-2-aminePharmacopoeial Synonyms
O-Pyrimidine Derivative Abacavir; Abacavir Related Compound DOther Synonyms
Abacavir 5′-4-Chloro-6-methylpyrimidine-2,5-diamine; 6-N-cyclopropyl-9-[(1R,4S)-4-[(2,5-diamino-6-chloropyrimidin-4-yl)oxymethyl]cyclopent-2-en-1-yl]purine-2,6-diamine; N6-Cyclopropyl-9-((1R,4S)-4-(((2,5-diamino-6-chloropyrimidin-4-yl)oxy)methyl)cyclopent-2-en-1-yl)-9H-purine-2,6-diamine; N6-Cyclopropyl-9-((1R,4S)-4-((2,5-diamino-6-chloropyrimidin-4-yloxy)methyl)cyclopent-2-enyl(-9H-purine-2,6 diamine; 9H-PURINE-2,6-DIAMINE, N6-CYCLOPROPYL-9-((1R,4S)-4-(((2,5-DIAMINO-6-CHLORO-4-PYRIMIDINYL)OXY)METHYL)-2-CYCLOPENTEN-1-YL)-Smiles
NC1=NC(NC2CC2)=C3N=CN([C@H]4C=C[C@@H](COC5=NC(N)=NC(Cl)=C5N)C4)C3=N1InChI
InChI=1S/C18H21ClN10O/c19-13-11(20)16(28-17(21)25-13)30-6-8-1-4-10(5-8)29-7-23-12-14(24-9-2-3-9)26-18(22)27-15(12)29/h1,4,7-10H,2-3,5-6,20H2,(H2,21,25,28)(H3,22,24,26,27)/t8-,10+/m1/s1Description
Abacavir EP Impurity B (CAS No: 1443421-69-9) or Abacavir O-Pyrimidine Impurity / Abacavir Related Compound D is synthesized by degradation of Abacavir which is a nucleoside reverse transcriptase inhibitor and Its mechanism include chain termination subsequent to incorporation into the growing polynucleotide strand. It is used in the treatment of HIV infection.References
Kurmi, Moolchand, et al. “Stability Behaviour of Antiretroviral Drugs and Their Combinations. 5: Characterization of Novel Degradation Products of Abacavir Sulfate by Mass and Nuclear Magnetic Resonance Spectrometry.” Journal of Pharmaceutical and Biomedical Analysis, vol. 134, Feb. 2017, pp. 372–84, https://doi.org/10.1016/j.jpba.2016.10.019. ?Vukkum, Pallavi. “Stress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the DeterminationRequest a Quote
"*" indicates required fields
Other products related to Abacavir impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
